Bausch + Lomb (BLCO) has drawn fresh attention after launching its Bi-Blade+ dual-port vitrectomy cutter in Europe, a device designed to increase vitreous flow and reduce cutter vibration within its Stellaris Elite surgical platform.

Despite the Bi-Blade+ launch and raised 2026 revenue guidance, Bausch + Lomb’s recent share price return has softened. The 90 day share price return is down 5.66%, while the 1 year total shareholder return sits at 36.08%, suggesting earlier momentum has cooled.

If you are looking beyond eye care technology, this could be a useful moment to see what else is attracting attention in healthcare AI by checking out 35 healthcare AI stocks.

With the stock down over the past quarter but still showing a 36.08% total shareholder return over one year and trading below the average analyst price target, is this a genuine opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 58.8% Undervalued

The leading narrative on Bausch + Lomb values the stock at $39.23, which is well above the last close at $16.18, setting up a significant gap between narrative fair value and current trading levels.

After reviewing historical filings, industry norms, and comparable companies:

A. This delay is unprecedented for this company.

There is no prior instance of an AGM result blackout of this length.

B. This delay is highly unusual for any public company.

AGM results are procedural, routine, and expected.

C. The lack of communication increases governance risk.

Shareholders cannot assess leadership legitimacy without vote results.

D. The silence itself becomes material.

When a company withholds information that is normally disclosed, the absence of disclosure becomes a signal.

The valuation story here leans heavily on robust profit margins, a steep earnings ramp up and a future earnings multiple that implies confidence in long term cash generation.

Result: Fair Value of $39.23 (UNDERVALUED)

However, this hinges on governance concerns around the AGM silence and on the fact that Bausch + Lomb currently reports a loss of US$360 million on US$5,101 million revenue.

Next Steps

If that mix of optimism and concern feels familiar, use it as a prompt to move quickly and verify the numbers yourself, starting with the 3 key rewards

Looking for more investment ideas?

Do not stop with one stock; broaden your watchlist using focused screeners that highlight different types of opportunities other investors could overlook.

• Zero in on potential turnaround stories by checking out 25 elite penny stocks with strong financials chasing stronger financial footing and room to surprise the market.
• Prioritise quality at a sensible price by using the 50 high quality undervalued stocks to spot companies with solid fundamentals that may trade below their underlying strength.
• Tilt toward resilience by reviewing the 71 resilient stocks with low risk scores and focus on stocks that score well on stability instead of waiting for headlines to catch up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.